LIVER FASt ™
Blood-based liver evaluation test that uses 10 biomarkers and advanced technology to determine the condition of the liver
- What is LIVERFASt™
- How it works
- What does it measure
- Clinical Validation
- Integration and Usability
What is LIVERFASt™?
LIVERFASt™ provides a score from 0.00 to 1.00 and its estimated grade or stage, similar to the histopathological scoring of the liver (based on the liver biopsy classification).
Alpha-2-Macroglobulin
Haptoglobin
Apolipoprotein A1
Total Bilirubin
GGT
ALT
AST
Fasting Glucose
Triglycerides
Total Cholesterol
How it Works
Simple and easy-to-do
Physician prescribes LIVERFASt™
Lab analyzes 10 biomarkers from 1 blood draw
Biomarker values plus age, height, weight, gender, are entered into the platform
LIVERFASt™ results are available immediately.
What does LIVERFASt™ Measure?
LIVERFASt™ takes inputs from 10 biomarkers and patient anthropometrics to generate a score from 0.00 to 1.00 that corresponds to the histopathological staging of a liver biopsy.
Fibrosis
STAGE
| FO | INTERPRETATION |
|---|---|
| No fibrosis | F1 |
| F2 | Advanced fibrosis |
| F1 | Significant fibrosis |
| F4 | Severe fibrosis/cirrhosis |
Activity
STAGE
| aO | INTERPRETATION |
|---|---|
| No activity | a1 |
| a2 | Moderate activity |
| a1 | Marked activity |
| a4 | Severe activity |
Steatosis
STAGE
| sO | INTERPRETATION |
|---|---|
| No steatosis (<5%) | s1 |
| s2 | Moderate steatosis (34-66%) |
| s3 | Marked steatosis (≥ 67%) |
Clinical Validation
LIVERFASt™ is clinically validated against different cohorts and can be used to test patients with different comorbidities.
LIVIRFASt Activity Test performance
MASLD population(n=223)
| Metric | Value |
|---|---|
| ADRDC (95% CI) | 0.79 (0.71-0.85) |
| Specificity | 0.85 |
| Sensitivity | 0.59 |
| Negative Predictive Value | 0.65 |
| Positive Predictive Value | 0.85 |
LIVIRFASt Fibrosis Test performance
MASLD population(n=223)
| Metric | Value |
|---|---|
| ADRDC (95% CI) | 0.867 (0.807-0.910) |
| Specificity | 0.85 |
| Sensitivity | 0.75 |
| Negative Predictive Value | 0.88 |
| Positive Predictive Value | 0.71 |
The concordance for cirrhosis with Liver Biopsy (n=452)
| Test | Positive |
|---|---|
| LIVERFASt | 67/95(71%) |
| LSM | 51/95(54%) |
| FIB-4 | 45/95(47%) |
Integration and Usability
LIVERFASt™ seamlessly integrates into any clinical or healthcare setting, enhancing liver health screening workflows without disrupting existing systems.
Interested in LIVERFASt™?
Sign up with us to receive exclusive brochures and posters that provide detailed insights into groundbreaking products.